Lido Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.50 M
- Revenue Growth 325.57%
- Profit Growth 43.29%
- Ebitda 133.34%
- Net Worth -29.89%
- Total Assets 127.78%
About Lido Pharma
Lido Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 May 2017 (Seven years and eight months 25 days old ). Its registered office is in Kolhapur, Maharashtra, India.
The Company is engaged in the Jewelry & Fashion Accessories Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Vinayak Mulik and Punam Ghatage serve as directors at the Company.
Company Details
- Location
Kolhapur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U33301PN2017PTC170704
- Company No.
170704
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 May 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Lido Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vinayak Mulik  | Director | 17-Feb-2022 | Current |
| Punam Ghatage | Director | 17-Feb-2022 | Current |
Financial Performance of Lido Pharma.
Lido Pharma Private Limited, for the financial year ended 2019, experienced significant growth in revenue, with a 325.57% increase. The company also saw a substantial improvement in profitability, with a 43.29% increase in profit. The company's net worth observed a substantial decline by a decrease of 29.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lido Pharma?
Unlock access to Lido Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0.50 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Mar 2019 | Others | ₹0.50 M | Open |
How Many Employees Work at Lido Pharma?
Unlock and access historical data on people associated with Lido Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lido Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lido Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
